PL373004A1 - Sposób wytwarzania pochodnych N-acylo-(epi)K5-amino-O-siarczanowych i produktów otrzymywanych tym sposobem - Google Patents

Sposób wytwarzania pochodnych N-acylo-(epi)K5-amino-O-siarczanowych i produktów otrzymywanych tym sposobem

Info

Publication number
PL373004A1
PL373004A1 PL03373004A PL37300403A PL373004A1 PL 373004 A1 PL373004 A1 PL 373004A1 PL 03373004 A PL03373004 A PL 03373004A PL 37300403 A PL37300403 A PL 37300403A PL 373004 A1 PL373004 A1 PL 373004A1
Authority
PL
Poland
Prior art keywords
epik5
derivatives
amine
sulfate
oversulfate
Prior art date
Application number
PL03373004A
Other languages
English (en)
Inventor
Pasqua Anna Oreste
Giorgio Zoppetti
Original Assignee
Glycores 2000 S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2002MI001345A external-priority patent/ITMI20021345A1/it
Priority claimed from IT2002MI001346A external-priority patent/ITMI20021346A1/it
Priority claimed from ITMI20021854 external-priority patent/ITMI20021854A1/it
Application filed by Glycores 2000 S.R.L. filed Critical Glycores 2000 S.R.L.
Publication of PL373004A1 publication Critical patent/PL373004A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL03373004A 2002-06-18 2003-06-17 Sposób wytwarzania pochodnych N-acylo-(epi)K5-amino-O-siarczanowych i produktów otrzymywanych tym sposobem PL373004A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI001345A ITMI20021345A1 (it) 2002-06-18 2002-06-18 Derivati epimerizzati del polissacaride k5 a elevatissimo grado di solfatazione
IT2002MI001346A ITMI20021346A1 (it) 2002-06-18 2002-06-18 Polisaccaridi a basso peso molecolare e procedimento per la loro preparazione
ITMI20021854 ITMI20021854A1 (it) 2002-08-27 2002-08-27 Polisaccaride supersolfatato a basso peso molecolare.

Publications (1)

Publication Number Publication Date
PL373004A1 true PL373004A1 (pl) 2005-08-08

Family

ID=29740492

Family Applications (3)

Application Number Title Priority Date Filing Date
PL03375088A PL375088A1 (pl) 2002-06-18 2003-06-17 Epimeryzowane pochodne K5-polisacharydu o bardzo wysokim stopniu siarczanowania
PL03373004A PL373004A1 (pl) 2002-06-18 2003-06-17 Sposób wytwarzania pochodnych N-acylo-(epi)K5-amino-O-siarczanowych i produktów otrzymywanych tym sposobem
PL03375087A PL375087A1 (pl) 2002-06-18 2003-06-17 Przesiarczanowany polisacharyd o niskim ciężarze cząsteczkowym

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL03375088A PL375088A1 (pl) 2002-06-18 2003-06-17 Epimeryzowane pochodne K5-polisacharydu o bardzo wysokim stopniu siarczanowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL03375087A PL375087A1 (pl) 2002-06-18 2003-06-17 Przesiarczanowany polisacharyd o niskim ciężarze cząsteczkowym

Country Status (15)

Country Link
US (4) US20050256079A1 (pl)
EP (3) EP1513880B1 (pl)
JP (3) JP2005536577A (pl)
CN (3) CN1671744A (pl)
AT (1) ATE485308T1 (pl)
AU (3) AU2003242881A1 (pl)
BR (3) BR0312182A (pl)
CA (3) CA2489862C (pl)
DE (1) DE60334617D1 (pl)
IL (2) IL165807A (pl)
MX (3) MXPA04012805A (pl)
NO (3) NO20050247L (pl)
NZ (3) NZ537216A (pl)
PL (3) PL375088A1 (pl)
WO (3) WO2003106505A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032498A1 (it) * 2003-12-17 2005-06-18 Pasqua Anna Oreste Polisaccaridi antitrombotici a basso peso molecolare e
ITMI20010397A1 (it) * 2001-02-27 2002-08-27 Giorgio Zoppetti Derivati altamente n,o-solfatati del polisaccaride k5 e loro preparazione
US20120253029A1 (en) 2002-06-18 2012-10-04 Pasqua Anna Oreste Process for the preparation of highly o-sulfated epimerized derivatives of k5 polysaccharide and intermediates therein
CN1671744A (zh) * 2002-06-18 2005-09-21 格利考斯2000有限公司 低分子量过硫酸化多糖
US8513407B2 (en) * 2002-06-18 2013-08-20 Glycores 2000 S.R.L. Process for the preparation of N-acyl-(epi)K5-amine-O-sulfate-derivatives and products thus obtained
ITMI20031618A1 (it) * 2003-08-06 2005-02-07 Inalco Spa Derivati polisaccaridici dotati di alta attivita'
FR2871476B1 (fr) * 2004-06-14 2011-04-01 Ifremer Derives depolymerises sulfates d'exopolysaccharides (eps) provenant de bacteries marines mesophiles, leur procede de preparation et leurs utilisations en regeneration tissulaire
FR2871379B1 (fr) * 2004-06-14 2006-09-29 Ifremer Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese
WO2007053794A2 (en) * 2005-10-21 2007-05-10 Bezwada Biomedical Llc Functionalized phenolic compounds and absorbable therefrom

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1141483B (it) * 1980-04-18 1986-10-01 Crinos Industria Farmaco Resina poliamminica per la separazione selettiva di eparina da altri glucosamminoglicani e procedimento per la sua preparazione
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
DE3787996T2 (de) * 1986-05-16 1994-03-03 Italfarmaco Spa Heparine, frei von E.D.T.A., Fraktionen und Fragmente von Heparin, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, welche diese enthalten.
EP0333243A3 (en) * 1988-03-10 1989-09-27 Akzo N.V. Sulphated k5 antigen and sulphated k5 antigen fragments
FR2669932B1 (fr) * 1990-12-03 1994-07-01 Sanofi Sa Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
GB2286193A (en) 1991-03-28 1995-08-09 Italfarmaco Spa Anticoagulants and processes for preparing such
FR2684385B1 (fr) * 1991-11-28 1997-08-01 Sanofi Elf Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IT1271057B (it) * 1994-11-04 1997-05-26 Inalco Spa Polisaccaridi aventi un elevato contenuto di acido iduronico
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
IT1282994B1 (it) * 1996-05-10 1998-04-03 Inalco Spa Derivati del polisaccaride k5 aventi elevata attivita' anticoagulante
IT1284143B1 (it) * 1996-09-06 1998-05-08 Istituto Scient Di Chimica E B Eparansolfati semi-sintetici ad elevata attivita' antimetastica e ridotto rischio emorragico
GB9620459D0 (en) 1996-10-01 1996-11-20 Mclaughlin Andrew Improvements in or relating to blocked isocyanates and their production
IT1289613B1 (it) * 1997-02-07 1998-10-15 Inalco Spa Polisaccaridi batterici o-solfatati
IT1290814B1 (it) * 1997-03-24 1998-12-11 Istituto Scient Di Chimica E B Glicosaminoglicani aventi elevata attivita' antitrombotica
US6329351B1 (en) * 1997-08-28 2001-12-11 Istituto Scientifico Di Chimica E Biochimica “G. Ronzoni” Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
US6388060B1 (en) * 1998-11-06 2002-05-14 Vascular Therapeutics Inc. Process for the sulfation of uronic acid-containing polysaccharides
US20020062019A1 (en) * 2000-03-30 2002-05-23 Pasqua Oreste Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
IT1318432B1 (it) * 2000-03-30 2003-08-25 Inalco Spa Glicosaminoglicani derivati dal polisaccaride k5 aventi elevataattivita' anticoagulante ed antitrombotica e processo per la loro
ITMI20032498A1 (it) * 2003-12-17 2005-06-18 Pasqua Anna Oreste Polisaccaridi antitrombotici a basso peso molecolare e
US20050027117A1 (en) * 2000-12-18 2005-02-03 Pasqua Oreste Anticoagulant and antithrombotic LMW-glycosaminoglycans derived from K5 polysaccharide and process for their preparation
ITMI20010397A1 (it) * 2001-02-27 2002-08-27 Giorgio Zoppetti Derivati altamente n,o-solfatati del polisaccaride k5 e loro preparazione
ITMI20010779A1 (it) * 2001-04-12 2002-10-12 Giorgio Zoppetti Uso di polisaccaridi batterici solfati atti all'inibizione dell'angiogenesi
ITMI20011633A1 (it) * 2001-07-27 2003-01-27 San Raffaele Centro Fond Uso di polisaccaridi batterici supersolfatati inibitori dell'hiv
ITMI20012200A1 (it) * 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
CN1671744A (zh) * 2002-06-18 2005-09-21 格利考斯2000有限公司 低分子量过硫酸化多糖
ITMI20032614A1 (it) * 2003-12-30 2005-06-30 Altergon Sa Nuova composizione comprendente cs

Also Published As

Publication number Publication date
CN1675250B (zh) 2012-11-14
IL165807A0 (en) 2006-01-15
NO20050247L (no) 2005-03-16
EP1519961A1 (en) 2005-04-06
BR0312179A (pt) 2005-04-05
NZ537216A (en) 2005-05-27
JP5053512B2 (ja) 2012-10-17
EP1517924A1 (en) 2005-03-30
BR0312197A (pt) 2005-04-05
DE60334617D1 (de) 2010-12-02
PL375088A1 (pl) 2005-11-14
NO20050244L (no) 2005-03-16
CA2489866A1 (en) 2003-12-24
AU2003240191A1 (en) 2003-12-31
CN1675249A (zh) 2005-09-28
WO2003106505A9 (en) 2004-02-26
EP1513880A1 (en) 2005-03-16
AU2003242881A1 (en) 2003-12-31
NO20050245L (no) 2005-03-16
US20050256079A1 (en) 2005-11-17
MXPA04012805A (es) 2005-08-19
AU2003240190B2 (en) 2009-07-09
US8193166B2 (en) 2012-06-05
US20060014718A1 (en) 2006-01-19
CN1671744A (zh) 2005-09-21
JP2005533878A (ja) 2005-11-10
US20050245736A1 (en) 2005-11-03
WO2003106506A1 (en) 2003-12-24
JP2005536577A (ja) 2005-12-02
CN1675250A (zh) 2005-09-28
CA2489870A1 (en) 2003-12-24
AU2003240190A1 (en) 2003-12-31
NZ537217A (en) 2005-09-30
US7838644B2 (en) 2010-11-23
PL375087A1 (pl) 2005-11-14
BR0312182A (pt) 2005-04-05
MXPA04012721A (es) 2005-08-15
ATE485308T1 (de) 2010-11-15
MXPA04012714A (es) 2005-08-15
IL165807A (en) 2011-10-31
JP2005530877A (ja) 2005-10-13
IL165808A0 (en) 2006-01-15
CA2489862A1 (en) 2003-12-24
EP1513880B1 (en) 2010-10-20
NZ537215A (en) 2006-11-30
CA2489862C (en) 2012-03-27
US20110021766A1 (en) 2011-01-27
WO2003106504A1 (en) 2003-12-24
WO2003106505A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
NO20050245L (no) Fremgangsmate for fremstilling av N-acyl-(epi)K5-amin-o-sulfat-derivater og de derved oppnadde produkter
SG131109A1 (en) Muteins of tear lipocalin
WO2003084922A8 (de) Acyl-4-carboxy-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
DE60025328D1 (de) Verfahren zur herstellung von mehrfach vernetzten hyaluronsäurederivaten
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
EA200400878A1 (ru) Новые эфиры флуоренкарбоновых кислот, способ их получения, а также их применение в качестве лекарственных средств
ES2181607T1 (es) Procedimiento para la reticulacion de acido hialuronico a polimeros.
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
DE69928219D1 (de) Lipasehemmende polymere
EA200200096A1 (ru) Новые производные витамина d с циклическими субструктурами в боковых цепях, способ и промежуточные продукты для их получения и их применение для получения лекарственных средств
BR9807936A (pt) Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
ES2189508T3 (es) Procedimiento para la preparacion de epotilon b y derivados, asi como productos intermedios.
AR032369A1 (es) Procedimiento para preparar 3-amino-2-cloro-4-metilpiridina
GB2440089A (en) Regeneration system its production and use
UA81649C2 (ru) Эфиры карбаминовой кислоты, которые имеют антихолинергическое действие
ATE488226T1 (de) Mahonia aquifolium extrakt, extraktionsverfahren und diesen enthaltende pharmazeutische zusammensetzung
ATE294865T1 (de) Identifizierung, produktion und verwendung von staphylokinase derivaten mit reduzierter immunogenizität und/oder reduzierter 'clearance'
BR9907837B1 (pt) composiÇço cosmÉtica, processo de preparaÇço de um produto extraÍdo com atividade estimuladora da produÇço de il-6 pelos queratinàcitos, utilizaÇço do mesmo e utilizaÇço de uma cepa de rhodotorula.
RS88704A (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof
ATE410173T1 (de) Produkt pflanzlichen ursprungs, das proanthocyane enthält, sowie verfahren zu seiner herstellung
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
FR2893504B1 (fr) Procede d'obtention d'un principe actif exhausteur de la resistance mecanique cutanee, principe actif et compositions
EA200401358A1 (ru) 2,5-бис-диамин-[1,4]бензохиноновые производные для лечения болезни альцгеймера, способ их получения и промежуточные продукты
AU1848401A (en) A novel method to produce human natural interferon-alpha

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)